Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.